Skip to main content

Table 5 Progressors and non-progressors to ESKD stratified by the presence and absence of eosinophilia in the study population

From: Eosinophilia and risk of incident end stage kidney disease

 

No Eosinophilia

≤ 4%

(n = 113)

Peripheral Eosinophilia

4–10%

(n = 38)

Peripheral Eosinophilia

≥10%

(n = 27)

P-value*

ESKD, n (%)

2 (2)

7 (18)

15 (56)

< 0.001

No ESKD, n (%)

111 (98)

31 (82)

12 (44)

 

Time to ESKD, median (IQR), months

74 (43)

32 (63)

36 (46)

0.14

Kidney tissue eosinophil

 n (%)

96 (74)

27 (71)

14 (52)

–

 mean (SD), hpf

3 (7)

22 (20)

19 (18)

< 0.001**

  1. *P-value calculated by analysis of variance (ANOVA) test of means for continuous variables and categorical variables. X2 test calculated for binary variables. P < 0.05 considered statistically significant
  2. Abbreviations: ESKD end-stage-kidney-disease
  3. Peripheral Eosinophilia is defined as eosinophils > 4% of blood leukocytes; Time to ESKD defined as months from the time of kidney biopsy
  4. **linear association of peripheral eosinophilia on tissue eosinophils per high-power field (hpf)
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us